Treatment outcomes for equine osteoarthritis with mesenchymal stromal cells and hyaluronic acid.

The research conducted a clinical study on the safety and efficacy of mesenchymal stromal cells (MSCs) in treating osteoarthritis in horses. The study concluded that the MSC treatment is safe, and although it didn’t show significant differences in lameness outcomes when compared to traditional hyaluronic acid (HA) treatment, it did show higher return rates to the same or higher work levels, suggesting further studies are needed with larger sample sizes.

Research Methods and Objectives

• The authors conducted a prospective, randomized clinical study on 27 client-owned horses suffering from osteoarthritis in the fetlock or carpus joints.
• The aim was to assess the safety and efficacy of equine umbilical cord-derived (eCB) MSCs as a treatment modality.
• The horses were randomly assigned to receive either 10 or 20 million eCB-MSCs mixed with HA or 3 mL of HA alone (used as a control).
• Lameness examinations were performed at baseline, then at 3 and 6 weeks post-treatment to measure the efficacy of the treatments.
• Any adverse reactions were evaluated 24-72 hours post-injection, and follow-up surveys were sent to owners at 18 weeks.

Findings and Conclusions

• The study showed no significant adverse reactions from the treatments, indicating the safety of using eCB-MSCs for treating osteoarthritis in horses.
• There were no significant differences in lameness outcomes between groups at 3 or 6 weeks, although all groups showed an overall improvement over time.
• The MSC + HA groups had higher return rates to the same or a higher work level than the HA-only group, although the differences were not statistically significant.
• The authors concluded that the unexpectedly high return-to-work rates in the HA (control) group might have affected the result, suggesting that a larger sample size would increase the power of the study to detect significant differences.
• Therefore, they suggested that future studies should consider larger sample sizes, approximately 30 horses per group, to obtain more conclusive results.

Implications of the Research

• The research adds valuable insights into the potential benefits of MSC and HA treatments in managing osteoarthritis in horses.
• Moreover, although not statistically significant, the study hints at the possibility of MSC-based treatments enabling horses to return to the same or a higher work level more frequently than traditional HA treatments.
• Therefore, further research involving larger sample sizes could establish the therapeutic potential and comparative advantages of MSCs over traditional HA treatments, which would contribute significantly to improving osteoarthritis management in horses.